Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
About this study
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.
- Condition
- Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma
- Tested
- Computed Tomography, Endoscopic Procedure, Involved-site Radiation Therapy (3 Fractions), Involved-site Radiation Therap...
- Sponsor
- Mayo Clinic
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 15
- Minimum age: 18 years
- Study condition: Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma
- Age ≥ 18 years
- Histological confirmation of indolent B-cell lymphoma that can include any of the following:
- Follicular lymphoma (grade 1 or 2 or 3A)
- Marginal zone lymphoma (nodal or extranodal)
- Follicle center lymphoma
- Any stage disease
- Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3
- Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only
- Provide written informed consent
- Ability to complete questionnaire(s) by themselves or with assistance
- Willing to return to enrolling institution for follow-up visits (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items
- Confirmation from radiation oncologist of suitability to participate in study
Exclusion 7
- Any of the following:
- Pregnant women
- Nursing women
- Women of childbearing potential who are unwilling to employ adequate contraception
- T-cell lymphoma
- Receiving treatment for small and chronic lymphocytic lymphoma
- Grade 3B follicular lymphoma
Where
7 sites, 7 recruiting
Mayo Clinic Health System in Albert Lea
Albert Lea, Minnesota, United States
Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, United States
Mayo Clinic Health System - Mankato
Mankato, Minnesota, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
and 1 more site on ClinicalTrials.gov
Contact
-
Clinical Trials Referral Office
855-776-0015 mayocliniccancerstudies@mayo.edu
Potential match only. Final eligibility is determined by the study team.